机构风向标 | 东诚药业(002675)2025年二季度机构持仓风向标

Core Insights - Dongcheng Pharmaceutical (002675.SZ) released its semi-annual report for 2025 on August 15, 2025, indicating significant institutional investment in the company [1] Institutional Holdings - As of August 14, 2025, a total of 10 institutional investors disclosed holdings in Dongcheng Pharmaceutical A-shares, with a combined holding of 219 million shares, representing 26.55% of the total share capital [1] - The top ten institutional investors include Yantai Dongyi Biological Engineering Co., Ltd., PACIFIC RAINBOW INTERNATIONAL, INC., Longgong (Shanghai) Machinery Manufacturing Co., Ltd., and others, with their combined holding ratio increasing by 1.45 percentage points compared to the previous quarter [1] Public Fund Activity - In this reporting period, two new public funds were disclosed compared to the previous quarter, namely Guotou Ruijin Healthcare Mixed A and Yinhua CSI All-Share Pharmaceutical and Health Index Enhanced Initiation Fund [1] - One public fund, the Fortune CSI 1000 Index Enhanced (LOF) A, was not disclosed in this period, indicating a reduction in public fund participation [1] Foreign Investment Trends - The report noted an increase in foreign investment, with one foreign fund, Hong Kong Central Clearing Limited, increasing its holdings slightly [1]